[December 12, 2014] |
|
Research and Markets: Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
Research and Markets (http://www.researchandmarkets.com/research/cb339x/recurrent_head)
has announced the addition of the "Recurrent
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014"
report to their offering.
This report provides comprehensive information on the therapeutic
development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma,
complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved
in the therapeutic development for Recurrent Head And Neck Cancer
Squamous Cell Carcinoma and special features on late-stage and
discontinued projects.
Reasons t buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Recurrent Head And Neck Cancer Squamous Cell
Carcinoma
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth
and focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Amgen Inc.
-
Genentech, Inc.
-
MedImmune, LLC
-
Novartis AG
-
Ono Pharmaceutical Co., Ltd.
-
Pfizer Inc.
-
Merck KGaA
-
Oncolytics Biotech Inc.
-
Panacea Biotec Limited
-
PCI (News - Alert) Biotech AS
-
Glycotope GmbH
-
VentiRx Pharmaceuticals, Inc.
-
Immunovative Therapies, Ltd.
-
AlphaMab Co., Ltd
For more information visit http://www.researchandmarkets.com/research/cb339x/recurrent_head
[ Back To TMCnet.com's Homepage ]
|